Results 111 to 120 of about 382,520 (299)

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity

Cellular Physiology and Biochemistry, 2018
Background/Aims: Although oxaliplatin is one of the most effective chemotherapeutic drugs used to treat colorectal cancer (CRC), long-term administration usually induces acquired drug resistance during the course of treatment.
Yongqiang Hua, Yaodong Zhu, Jijie Zhang, Zhenfeng Zhu, Zhouyu Ning, Hao Chen, Luming Liu, Zhen Chen, Zhiqiang  Meng   +8 more
doaj   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source

Intracellular signaling dynamics during apoptosis execution in the presence or absence of X-linked-inhibitor-of-apoptosis-protein

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2008
X-linked-inhibitor-of-apoptosis-protein (XIAP) is the most potent intracellular inhibitor of caspases-9, -3 and -7. While highly elevated XIAP levels reduce the apoptotic response to various stimuli, the potency of physiological XIAP expression to control caspase activation and the consequences of XIAP deficiency on apoptosis execution remain ...
O'Connor, Carla L., Anguissola, Sergio, Huber, Heinrich J., Dussmann, Heiko, Prehn, Jochen H.M., Rehm, Markus   +5 more
openaire   +2 more sources

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Characterization of bivalent peptides that bind to X‐linked inhibitor of apoptosis protein

The FASEB Journal, 2010
X‐linked inhibitor of apoptosis protein (XIAP) is a regulator of programmed cell death and an important target in the development of cancer therapeutics. Biochemical studies reveal that the homodimeric protein Smac, the natural binding partner of XIAP, binds to XIAP via simultaneous contact to the BIR2 and BIR3
Kelsey Speer, Kathryn Splan
openaire   +1 more source

TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis. [PDF]

, 2019
TNFα-related apoptosis-inducing ligand (TRAIL), specifically initiates programmed cell death, but often fails to eradicate all cells, making it an ineffective therapy for cancer.
Baskar, Reema, Bendall, Sean C, Favaro, Patricia, Fienberg, Harris G, Green, Douglas R, Khair, Zumana, Kimmey, Sam, Nolan, Garry P, Plevritis, Sylvia   +8 more
core  

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy [PDF]

, 2014
BRCA1, a key factor in homologous recombination repair may also regulate base excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.
Abdel-Fatah, TMA, Agarwal, D, Albarakati, N, Alsubhi, N, Arora, A, Ball, G, Caldas, C, Chan, S, Doherty, R, Ellis, IO, Green, A, Madhusudan, S, Moseley, P, Perry, C, Rakha, EA, Russell, R, Seedhouse, C   +16 more
core   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Regulation of eosinophilia and allergic airway inflammation by the glycan-binding protein galectin-1 [PDF]

, 2016
Galectin-1 (Gal-1), a glycan-binding protein with broad antiinflammatory activities, functions as a proresolving mediator in autoimmune and chronic inflammatory disorders. However, its role in allergic airway inflammation has not yet been elucidated.
Abramoff, Ada G. Blidner, Amrita Rao, Boehme, Gabriel A. Rabinovich, Ge, Ha, He, Idil Bastan, Matsuura, P. Sriramarao, Rabinovich, Savita P. Rao, Sung Gil Ha, Xiao Na Ge, Yana G. Greenberg   +15 more
core   +1 more source